

**CORDLIFE GROUP LIMITED**  
(Company Registration No.: 200102883E)  
(Incorporated in the Republic of Singapore)

---

**UPDATE ON REQUISITION NOTICES**

---

The board of directors (the "**Board**") of Cordlife Group Limited (the "**Company**") refers to its announcement dated 21 March 2024 in relation to, among others, the requisition notices received by the Company ("**21 March 2024 Announcement**").

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as in the 21 March 2024 Announcement.

**1. FIRST REQUISITION NOTICE**

In relation to the First Requisition Notice, the Company has verified the shareholding of Phillip Securities as nominee of NJXJK (the "**First Requisitioning Member**"), and has confirmed that the First Requisition Notice has been deposited at the registered office of the Company.

A copy of the First Requisition Notice, including the accompanying Appendix which sets out the First Requisitioning Member's grounds for the resolutions set out in the First Requisition, is enclosed in **Annex A** to this announcement.

With respect to paragraph 1(a) of the Appendix to the First Requisition Notice which makes reference to a letter dated 23 February 2024 sent by SAC Capital Private Limited ("**SAC Capital**") on NJXJK's behalf to the Company (the "**First SAC Letter**"), the Board wishes to update shareholders of the Company ("**Shareholders**") of the following:

- (a) The Company had on 23 February 2024 received the First SAC Letter notifying that NJXJK is currently reviewing its shareholding in the Company with the possibility of making an offer (either by itself or through its related companies) for the ordinary shares in the capital of the Company, other than those already owned, controlled or agreed to be acquired by NJXJK and parties acting in concert with NJXJK (the "**Potential Offer**"), and SAC Capital is acting as financial adviser to NJXJK in relation to the Potential Offer.
- (b) The First SAC Letter stated that no firm decision has been reached by NJXJK as to whether or not to make the Potential Offer and there is no certainty or assurance that any such offer would be made. In addition, the First SAC Letter provides that nothing in the First SAC Letter shall be construed as NJXJK having a firm intention to make an offer for shares in the Company under the Singapore Code on Take-overs and Mergers (the "**Code**").
- (c) The First SAC Letter also states that NJXJK will inform the Company of any material updates and in the meantime, NJXJK wishes to highlight for the attention of the Board, Rule 5 of the Code.

- (d) Under the Code, following an approach to the board of an offeree company which may or may not lead to an offer, the primary responsibility for making an announcement will normally rest with the board of the offeree company. In particular, an announcement is required when the offeree company is the subject of rumour or speculation about a possible offer, or there is undue movement in its share price or a significant increase in the volume of share turnover, whether or not there is a firm intention to make an offer. A movement of approximately 20% above the lowest share price since the time of the approach or above an appropriate market index should be regarded as untoward.
- (e) Upon receipt of the First SAC Letter, the Board had obtained legal advice stating, among others, that if Rule 703(3) of the listing rules of the Singapore Exchange Securities Trading Limited ("**SGX Listing Rules**") was applicable and there was no unusual trading activity of the Company's shares at the relevant time, there was no strict requirement under the SGX Listing Rules or the Code for the Board to make an announcement on the receipt of the First SAC Letter. Nonetheless, the Board can also opt to voluntarily release an announcement on the First SAC Letter.
- (f) The Company had subsequently received a letter dated 22 March 2024 from SAC Capital (the "**Second SAC Letter**", and together with the First SAC Letter, the "**SAC Letters**") updating that as of the date of the Second SAC Letter, NJXJK is currently still reviewing the Potential Offer. The Second SAC Letter further repeats the points set out in paragraphs (b) and (c) above from the First SAC Letter.

Mr Zhai Lingyun and Ms Chen Xiaoling, both of whom are Non-Independent Non-Executive Directors of the Company, are nominee directors of NJXJK. In this regard, both Mr Zhai Lingyun and Ms Chen Xiaoling have recused themselves from all deliberations and decisions of the Company relating to the First Requisition Notice and the SAC Letters.

Save as disclosed in the foregoing paragraph, and other than their respective interests arising by way of their shareholdings and/or directorships in the Company, none of the Directors and the substantial shareholders of the Company whose interests such Directors represent (if any) or their associates have any interest, direct or indirect, in the matters set out in the SAC Letters.

The Company will proceed to commence preparations to convene an EGM or table the resolutions in the First Requisition Notice at the AGM (as the case may be) pursuant to the First Requisition Notice and the Companies Act 1967 of Singapore ("**Companies Act**") in due course, and will update Shareholders as and when there are further developments.

**In the meantime, Shareholders and potential investors should exercise caution when dealing in the shares of the Company. In particular, there is no certainty or assurance that the Potential Offer will be made or that any transaction will materialise as a result of the First SAC Letter and/or the Second SAC Letter. They should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.**

## **2. SECOND REQUISITION NOTICE**

In relation to the Second Requisition Notice, the Company has obtained legal advice that the requisitions under the Second Requisition Notice are invalid as TransGlobal is not a "member" of the Company (as defined under the Companies Act) as at the date of the Second Requisition Notice, and accordingly, is not entitled to requisition an EGM of the Company under Section 176 of the Companies Act or to the circulation of resolutions under Section 183 of the Companies Act at the upcoming AGM. A copy of the Second Requisition Notice is enclosed in the **Annex B** to this announcement.

In view of the foregoing, the Company will not be tabling any resolutions contained in the Second Requisition Letter to Shareholders, and the Board will not be convening any EGM pursuant to the Second Requisition Letter. The Board has accordingly informed representatives of TransGlobal of the above.

For and on behalf of the Board  
**CORDLIFE GROUP LIMITED**

Low Mei Wan  
Company Secretary

24 March 2024

**ANNEX A**

***First Requisition Notice***

Date: 13 March 2024

**FOR IMMEDIATE ATTENTION  
BY HAND**

**CORDLIFE GROUP LIMITED**  
1 Yishun Industrial Street 1  
#06-01/09 A'Posh Bizhub  
Singapore 768160

Attention: Board of Directors / Company Secretary

Dear Sirs

**CORDLIFE GROUP LIMITED (THE "COMPANY"):**

- (1) REQUISITION TO CONVENE AN EXTRAORDINARY GENERAL MEETING PURSUANT TO SECTION 176 OF THE COMPANIES ACT 1967 OF SINGAPORE ("ACT")**
- (2) NOTICE OF MEMBERS' RESOLUTIONS PURSUANT TO SECTION 183 OF THE ACT**
- (3) SPECIAL NOTICE PURSUANT TO SECTION 152(2) READ WITH SECTION 185 OF THE ACT**

- 
1. We, the undersigned, are holding, as the date hereof, 51,870,000 ordinary shares in the capital of the Company ("**Relevant Shares**") as nominee for Nanjing Xinjiekou Department Store Co., Ltd. ("**NJXJK**"), such shares representing not less than 10% of the total number of paid-up shares carrying voting rights at general meetings of the Company.
  2. As a member of the Company and for and on behalf of NJXJK in respect of the Relevant Shares, we hereby give **SPECIAL NOTICE** to the Company and **REQUISITION** the directors of the Company to convene an extraordinary general meeting of the Company ("**EGM**") as soon as practicable but in any case not later than two (2) months after receipt of the notice hereof pursuant to an exercise of our rights as member of the Company pursuant to Section 176 of the Act.
  3. The objects of the EGM are to requisition the Company to table the following resolutions (collectively, the "**Proposed Resolutions**") for its shareholders to consider, and if thought fit, pass them at the EGM to be convened:
    - (a) **"ORDINARY RESOLUTION 1"**  
*The removal of Dr Ho Choon Hou as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*
    - (b) **"ORDINARY RESOLUTION 2"**  
*The removal of Yeo Hwee Tiong as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*
    - (c) **"ORDINARY RESOLUTION 3"**  
*The removal of Cheong Tuck Yan Titus Jim as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*
    - (d) **"ORDINARY RESOLUTION 4"**  
*The removal of Joseph Wong Wai Leung as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*

(e) "ORDINARY RESOLUTION 5"

*The appointment of Dato' Dr Teo Tong Kooi as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*<sup>(1)</sup>

(f) "ORDINARY RESOLUTION 6"

*The appointment of Dr Xu, Tianhong as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*<sup>(2)</sup>

(g) "ORDINARY RESOLUTION 7"

*The appointment of Cai, Yong as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."*<sup>(3)</sup>

(h) ADDITIONAL ORDINARY RESOLUTION(S)

Such additional ordinary resolutions for the removal of any other director(s) of the Company who may have been appointed between the date of this notice and the date of the EGM, effective immediately upon the conclusion of the EGM.

4. All the Proposed Resolutions shall be voted on individually by the members of the Company at the EGM.
5. Please immediately proceed to convene the EGM as soon as practicable. If the EGM is not convened prior to the upcoming annual general meeting of the Company ("**AGM**"), this Letter shall also serve as a **SPECIAL NOTICE** to the Company and we, the undersigned being a member of the Company holding, as the date hereof, not less than 5% of the total number of paid-up shares carrying voting rights at general meetings of the Company, hereby **REQUISITION** the directors of the Company to circulate the Proposed Resolutions (with the necessary amendments to amend any reference from "EGM" to "AGM") to be voted on at the AGM pursuant to an exercise of our rights as member of the Company pursuant to Section 183 of the Act.
6. For the avoidance of doubt, this notice also constitutes **SPECIAL NOTICE** pursuant to Section 152(2) read with Section 185 of the Act in respect of Ordinary Resolutions 1, 2, 3 and 4 and the Additional Ordinary Resolution(s).
7. In accordance with Section 152(2) of the Act, please also immediately send a copy of this notice to the directors referred to in Ordinary Resolutions 1, 2, 3 and 4 and the Additional Ordinary Resolution(s), and inform them that they shall be entitled to be heard on the resolution(s) relating to each of them at the EGM or the AGM (as the case may be). Kindly inform us whether any of the directors will be making representations in writing pursuant to Section 152(3) of the Act, and if so, provide us with the representations. We reserve our right to respond to any representations in writing that may be made by the directors referred to in Ordinary Resolutions 1, 2, 3 and 4 and the Additional Ordinary Resolution(s).
8. We are instructed by NJXJK to bring to the attention of the shareholders of the Company their message to fellow shareholders of the Company, setting out grounds for the Proposed Resolutions, as set out in the Appendix hereto. In particular, the profiles and intended roles of the proposed directors as referred to in Ordinary Resolutions 5, 6 and 7 are also set out in the Appendix. Each proposed director has also signed a written notice of their willingness to be elected and signifying their candidature for office which are lodged with the Company, together with this Letter.

<sup>1</sup> Dato' Dr Teo Tong Kooi will, upon appointment as a director of the Company, be designated as an independent and non-executive director of the Company.

<sup>2</sup> Dr Xu, Tianhong will, upon appointment as a director of the Company, be designated as an independent and non-executive director of the Company.

<sup>3</sup> Cai, Yong will, upon appointment as a director of the Company, be designated as an independent and non-executive director of the Company.

9. Please include this Letter and its Appendix in any circular which may be issued by the Company to all members of the Company in relation to the EGM which has been requisitioned by the undersigned requisitioning member.
10. If the Proposed Resolutions will be voted on at the AGM pursuant to Section 183 of the Act, please also circulate the statements set out in the Appendix hereto (each statement being less than 1,000 words with respect to the matter referred to the resolution(s) to which it relates) to all members of the Company entitled to have notice of any general meeting sent to them in accordance with Section 183(1)(b) of the Act (the "**Accompanying Statements**").
11. Please also find attached a cheque for S\$10,000 payable to the Company pursuant to Section 183(4)(b) of the Act, being a sum reasonably sufficient to meet the Company's expenses in circulating the Proposed Resolutions and the Accompanying Statements to all members of the Company. Please return the balance of the monies to us after deducting the reasonable expenses incurred in circulating the Proposed Resolutions and the Accompanying Statements to all members of the Company or if the directors of the Company proceed to convene the EGM pursuant to Section 176 of the Act.
12. All our rights are expressly reserved.

Yours faithfully

For and on behalf of  
**PHILLIP SECURITIES PTE LTD**  
(Company Registration Number: 197501035Z)

A handwritten signature in blue ink, appearing to read 'Luke Lim Wen Jiang', is written over a horizontal line. A small checkmark is visible to the right of the signature.

Director

Name: Luke Lim Wen Jiang  
No. of Shares: 51,870,000  
(as instructed by Nanjing Xinjiekou Department Store Co., Ltd.)



## APPENDIX

The message to shareholders of the Company by NJXJK comprising the Accompanying Statements and setting out grounds for the Proposed Resolutions and respective profiles of the proposed directors is set out below, and any reference to "we", "us" and "our" in this Appendix is a reference to NJXJK.

### 1. Statement supporting Ordinary Resolutions 1, 2, 3 and 4

- (a) As mentioned in the letter dated 23 February 2024 sent by SAC Capital Private Limited on our behalf to the Company, we have been monitoring with concern the recent developments of the Company. The Company is currently in crisis mode. The Company is currently under suspension imposed by the Ministry of Health of Singapore ("**MOH**") from the collection, testing, processing and/or storage any new cord blood and human tissues, or provide any new types of tests to patients.<sup>1</sup> This is the Company's lifeline and potentially a fatal hit on our reputation within the cord blood banking industry. The future of the Company hinges on its ability to reinstate our operations and regain the trust of the public, through qualified and focused leadership.
- (b) We note with grave concern that the Company announced at one point that certain members of the management team were aware of the irregular temperatures in one tank in June 2022, which was only escalated to the Audit Committee and the board of directors of the Company ("**Board**") eight months later in February 2023.<sup>2</sup> This underscores the lack of oversight which has led to the current crisis faced by the Company. We are of the view that this also arose from a lack of qualified and relevant experience on the Board and management level in dealing with operational and governance issues.
- (c) As a result of how the existing Board has managed the Company, the Company has had to deal with various inquiries by MOH, the SGX-ST as well as numerous adverse publicity by the media against the Company. It is of paramount importance for the Company to immediately conduct a thorough and independent investigation into these critical lapses, to prevent recurrence and to restore the trust and confidence of the Company's stakeholders. In this regard, our nominee directors, namely Ms Chen Xiaoling and Mr Zhai Lingyun ("**Nominee Directors**"), had suggested that the Board appoint an external consultant to carry out an independent investigation and to report their findings and recommendations to the Board. Their suggestion was not supported by the other directors of the Company.
- (d) After the resignation of the former Chief Executive Officer ("**CEO**"), Ms Tan Poh Lan, our Nominee Directors had also proposed that the Board conduct an executive search and appoint a CEO with the requisite qualifications, expertise and experience in the medical field to lead the Company through the current crisis as well as to prepare for the future.<sup>3</sup> We note that the views of our Nominee Directors are also shared by members of the public.<sup>4</sup> Their suggestion was again not supported by the other directors of the Company and our Nominee Directors abstained on the Board's decision to appoint Mr Yiu as CEO.<sup>5</sup> Despite this, the majority of the Board pushed through the

---

<sup>1</sup> Press release published by MOH on 30 November 2023 titled "*Investigation of Cordlife Group Limited for Suboptimal Storage Temperature for Cryopreserved Cord Blood*" (available on the MOH website: <https://www.moh.gov.sg/news-highlights/details/investigation-of-cordlife-group-limited-for-suboptimal-storage-temperature-for-cryopreserved-cord-blood>).

<sup>2</sup> Announcement published the Company on 10 December 2023 (available on the website of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"): <https://links.sgx.com/FileOpen/CGL%20-%20Announcement%20-%20Response%20to%20SGX%20Query.ashx?App=Announcement&FileID=780385>).

<sup>3</sup> Announcement published the Company on 29 February 2024 (available on the website of the SGX-ST: <https://links.sgx.com/FileOpen/CGL%20-%20Further%20Update%20to%20Announcement.ashx?App=Announcement&FileID=790684>).

<sup>4</sup> Media article published by Navene Elangovan on 27 February 2024 titled "*Cordlife needs a fresh start amid its ongoing scandal, not 'old blood' in a new bottle*" (available on The Business Times website: <https://www.businesstimes.com.sg/opinion-features/columns/cordlife-needs-a-fresh-start-amid-its-ongoing-scandal-not-old-blood-in-a-new-bottle>).

<sup>5</sup> Please refer to Footnote 3 above.

appointment of Mr Ivan Yiu Pang Fai as the new CEO, despite his lack of qualifications, expertise and experience in the medical field.

- (e) Given that our Nominee Directors have been unable to agree with the other directors on the handling of the crisis faced by the Company and who should be the CEO to lead the Company out of the crisis, it is now incumbent on us as shareholders and long-term investors to take action and save the Company by exercising our right to convene a general meeting to effect a reconstitution of the Board, to appoint qualified individuals with the requisite leadership and experience to bolster its ability to navigate through the current crisis and to restore confidence in the Company. Once the Board is reconstituted with the support of fellow shareholders, the Board will evaluate the evolving needs of the Group and where necessary, appoint additional directors to enhance the mix of skills, knowledge, geographical, gender and other aspects of diversity.
- (f) In this connection, we wish to highlight that we are a company based in the People's Republic of China ("PRC") and listed on the Shanghai Stock Exchange. We have a majority stake in Shandong Qilu Stem Cell Engineering Co. Ltd., a PRC company which provides health and allied services and operates a cord blood bank jointly with Qilu Hospital of Shandong University (which is currently storing approximately 800,000 cord blood units), giving us access to a strong network of professionals and enterprises with relevant technical expertise in the cord blood storage services field. If the shareholders support our Proposed Resolutions to reconstitute the Board, we will be able to tap on our resources in the cord blood storage services field to help the Company navigate through the current crisis and restore confidence in the Company.

## **2. Statement supporting Ordinary Resolution 5**

It is proposed that Dato' Dr Teo Tong Kooi will, upon appointment as a director of the Company, be designated as an independent and non-executive director of the Company.

Dato' Dr Teo is currently the Chief Executive Officer of DPS Corporate Advisory Company Limited (a member of Head International Group), a leading consulting firm in the PRC which provides financial, business and consulting services, post investment management services, restructuring and turnaround management. Dato' Dr Teo has a broad range of industry experience across multinational corporates and conglomerates, with 16 years in the corporate and commercial banking sector, 8 years in the manufacturing sector and 9 years in the property development and real estate investment sector. Dato' Dr Teo has also held senior leadership positions at various multinational corporations, having served as Managing Director of Guocoland (China) Ltd., Chief Executive Officer and Director of Hong Leong Asia Ltd, Singapore Managing Director of Tasek Corporation Bhd, Malaysia, Chief Operating Officer of Hong Leong Bank Malaysia, and Head of Corporate Banking, Deutsche Bank AG, Malaysia. He has also served as an Independent Non-Executive Director of Bank of America Malaysia as well as an Investment Committee Member of Isola Capital Ltd, and Octville Capital Asia, which provided him with multiple opportunities to interact with and address the concerns of regulators and investors across multiple jurisdictions.

Dato' Dr Teo graduated from Golden Gate University, San Francisco, California, USA, with a Bachelor of Science in Marketing Management and a Master of Business Administration. Dato' Dr Teo also graduated with a Doctor of Professional Studies in Management jointly offered by the Gabelli School of Business, New York Fordham University, USA, and the National School of Development, Peking University, PRC.

## **3. Statement supporting Ordinary Resolution 6**

It is proposed that Dr Xu, Tianhong will, upon appointment as a director of the Company, be designated as an independent and non-executive director of the Company.

Dr Xu is the founder and currently the CEO of Base Therapeutics Group Holding Limited, a company based in the United States of America ("US") specialising in the use and design of

cell and gene editing technology to treat cancerous diseases. He is concurrently the founding partner at Virtus Inspire Ventures, a boutique venture capital firm focusing on early-stage medical technologies companies across the PRC, the US and Israel. Dr Xu has experience in engaging with various public and private stakeholders across different levels in the medical industrial clusters. Trained as a medical doctor and researcher, Dr Xu previously served as a Medical Industry Expert for the United Nations Industrial Development Organisation (UNIDO), where he directed the upgrade of medical industrial clusters in the PRC through investment promotion, technology transfer and management consulting. Prior to his time at UNIDO, Dr Xu was also the Principal Scientist and Lab Director of GE Healthcare's next-generation sequencing department and a research scientist at the Texas Children's Hospital in US.

Dr Xu holds a PhD in Molecular and Human Genetics conferred by Baylor College of Medicine in Houston, Texas, US and a M.D. and M.S. from Fudan University, PRC.

#### **4. Statement supporting Ordinary Resolution 7**

It is proposed that Mr Cai, Yong will, upon appointment as a director of the Company, be designated as an independent and non-executive director of the Company.

Mr Cai is currently the Chairman and Executive Director of Beijing Shan Shi Investment Management Company, a Chinese company specialising in asset management and bankruptcy restructuring of large-scale enterprises in the industrial and manufacturing sectors, providing assistance to struggling businesses to overcome challenges to their business. Mr Cai has management experience in multinational corporations as well as large state-owned and private enterprises in the PRC, particularly in financial management, risk management and project management.

Mr Cai was previously the founding managing partner of Unicom Kaixing Fund, a leading multibillion-CNY private equity industry fund which he co-founded with China Unicom Group in 2018. The fund primarily invests in the 5G industry ecosystem and related application fields and counts itself among one of the largest shareholders and/or investors in several listed technology companies. Prior to Unicom Kaixing Fund, Mr Cai served as the Treasury Director, Financing General Manager, and Vice President of Financial Services of Digital China Holdings Limited and Digital China Group Limited, where he was responsible for the organisations' risk management, treasury, finance, and business transformation.

Mr Cai graduated with a Bachelor of Accountancy from Renmin University of China, Beijing, PRC, a Master of Business Administration from Tsinghua University School of Economics and Management, Beijing, PRC, and holds a PhD in History conferred by Peking University, Beijing, PRC.

Date: 13 March 2024

**CORDLIFE GROUP LIMITED**

1 Yishun Industrial Street 1  
#06-01/09A'Posh BizHub  
Singapore 768160

**BY HAND**

Attention: Board of Directors / Company Secretary

Dear Sirs

**DECLARATION OF WILLINGNESS TO ACT AS DIRECTOR OF CORDLIFE GROUP LIMITED (THE "COMPANY")**

I, Teo Tong Kooi (NRIC No. S2735562E) of 261 Bukit Timah Road #08-05 Goodwood Residence, Singapore 259703, hereby declare my willingness to stand for election for the position of director of the Company at the general meeting (whether at the annual general meeting or the extraordinary general meeting of the Company) to be convened and signifying my candidature for the office.

*[the remainder of this page is intentionally left blank]*

This declaration is hereby given by me and signed by my hand:

A handwritten signature in black ink, appearing to read 'Teo Tong Kooi', with a long horizontal flourish extending to the right.

---

Name: Teo Tong Kooi

Date: 13 March 2024

**CORDLIFE GROUP LIMITED**

1 Yishun Industrial Street 1  
#06-01/09A'Posh BizHub  
Singapore 768160

**BY HAND**

Attention: Board of Directors / Company Secretary

Dear Sirs

**DECLARATION OF WILLINGNESS TO ACT AS DIRECTOR OF CORDLIFE GROUP LIMITED (THE "COMPANY")**

I, Xu, Tianhong (People's Republic of China Passport No. EJ4494011) of Room 1705, No. 4, Lane 567, Chezhan North Road, Hongkou District, Shanghai, China, hereby declare my willingness to stand for election for the position of director of the Company at the general meeting (whether at the annual general meeting or the extraordinary general meeting of the Company) to be convened and signifying my candidature for the office.

This declaration is hereby given by me and signed by my hand:

DocuSigned by:  
*Xu Tianhong*  
E00A3DF82A32453...

---

Name: Xu, Tianhong

Date: 13 March 2024

**CORDLIFE GROUP LIMITED**  
1 Yishun Industrial Street 1  
#06-01/09A'Posh BizHub  
Singapore 768160

**BY HAND**

Attention: Board of Directors / Company Secretary

Dear Sirs

**DECLARATION OF WILLINGNESS TO ACT AS DIRECTOR OF CORDLIFE GROUP LIMITED (THE "COMPANY")**

I, Cai, Yong (People's Republic of China Passport No. EE0019228) of No. 178, Beiyuan Road, Chaoyang District, Beijing, China, hereby declare my willingness to stand for election for the position of director of the Company at the general meeting (whether at the annual general meeting or the extraordinary general meeting of the Company) to be convened and signifying my candidature for the office.



This declaration is hereby given by me and signed by my hand:

A handwritten signature in blue ink, appearing to be the Chinese characters '蔡勇' (Cai Yong), written in a cursive style.

Name: Cai, Yong

**ANNEX B**

***Second Requisition Notice***

Date: 18 March 2024

CORDLIFE GROUP LIMITED  
1 Yishun Industrial Street 1 #06-01/09  
A'Posh Bizhub  
Singapore 768160

FOR IMMEDIATE ATTENTION BY EMAIL

Attention: Board of Directors / Company Secretary

Dear Sirs,

CORDLIFE GROUP LIMITED (THE COMPANY"):

- (1) REQUISITION TO CONVENE AN EXTRAORDINARY GENERAL MEETING PURSUANT TO SECTION 176 OF THE COMPANIES ACT 1967 OF SINGAPORE ("ACT")
  - (2) NOTICE OF MEMBERS' RESOLUTIONS PURSUANT TO SECTION 183 OF THE ACT
  - (3) SPECIAL NOTICE PURSUANT TO SECTION 152(2) READ WITH SECTION 185 OF THE ACT
- 

1. We, the undersigned, are holding, as the date hereof, 71,460,300 ordinary shares in the capital of the Company ("Relevant Shares") TRANSGLOBAL REAL ESTATE GROUP, LTD. ("TG"), such shares representing not less than 27.9% of the total number of paid-up shares carrying voting rights at general meetings of the Company.
2. In respect of the Relevant Shares, we hereby give SPECIAL NOTICE to the Company and REQUISITION the directors of the Company to convene an extraordinary general meeting of the Company ("EGM") as soon as practicable but in any case, not later than two (2) months after receipt of the notice hereof pursuant to an exercise of our rights as member of the Company pursuant to Section 176 of the Act. 3. The objects of the EGM are to requisition the Company to table the following resolutions (collectively, the "Proposed Resolutions") for its shareholders to consider, and if thought fit, pass them at the EGM to be convened:

(a) ORDINARY RESOLUTION 1

To reject the Proposed Resolutions contained in SECTION 3 in the Requisition Notice received on 14<sup>th</sup> March 2024 from Phillip Securities, as follows:

- (a) Ordinary Resolution 1
- (b) Ordinary Resolution 2
- (c) Ordinary Resolution 3
- (d) Ordinary Resolution 4
- (e) Ordinary Resolution 5
- (f) Ordinary Resolution 6
- (g) Ordinary Resolution 7; and
- (h) Additional Ordinary Resolutions

and to replace these Proposed Resolutions with the following resolutions;

(a) ORDINARY RESOLUTION 2

The removal of Lingyun Zhai as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved."

(b) ORDINARY RESOLUTION 3

The removal of Shally Chen (陳法笠) as a director of the Company effective immediately upon conclusion of the EGM be and is hereby approved.

(c) ADDITIONAL ORDINARY RESOLUTION(S)

Such additional ordinary resolutions for the removal of any other director(s) of the Company who may have been appointed between the date of this notice and the date of the EGM, effective immediately upon the conclusion of the EGM.

3. All the Proposed Resolutions shall be voted on individually by the members of the Company at the EGM.
4. Please immediately proceed to convene the EGM as soon as practicable. If the EGM is not convened prior to the upcoming annual general meeting of the Company ("AGM"), this Letter shall also serve as a SPECIAL NOTICE to the Company and we, the undersigned being a member of the Company holding, as the date hereof, not less than 5% of the total number of paid-up shares carrying voting rights at general meetings of the Company, hereby REQUISITION the directors of the Company to circulate the Proposed Resolutions (with the necessary amendments to amend any reference from 'EGM' to "AGM") to be voted on at the AGM pursuant to an exercise of our rights as member of the Company pursuant to Section 183 of the Act.
5. For the avoidance of doubt, this notice also constitutes SPECIAL NOTICE pursuant to Section 152(2) read with Section 185 of the Act in respect of Ordinary Resolutions 1, 2, and 3 and the Additional Ordinary Resolution(s).
6. In accordance with Section 152(2) of the Act, please also immediately send a copy of this notice to the directors referred to in Ordinary Resolutions 1, 2 and 3 and the Additional Ordinary Resolution(s), and inform them that they shall be entitled to be heard on the resolution(s) relating to each of them at the EGM or the AGM (as the case may be). Kindly inform us whether any of the directors will be making representations in writing pursuant to Section 152(3) of the Act, and if so, provide us with the representations. We reserve our right to respond to any representations in writing that may be made by the directors referred to in Ordinary Resolutions 1, 2 and 3 and the Additional Ordinary Resolution(s).
7. Please include this Letter in any circular which may be issued by the Company to all members of the Company in relation to the EGM which has been requisitioned by the undersigned requisitioning shareholder. If the Proposed Resolutions will be voted on at the AGM pursuant to Section 183 of the Act, please also circulate to all members of the Company entitled to have notice of any general meeting sent to them in accordance with Section 183(1b) of the Act.
8. The rationale of the Proposed Resolution will be circulated to all shareholders within the timelines which will be in compliance with all regulatory requirements.

Yours faithfully,  
For and on behalf of TRANSGLOBAL REAL ESTATE GROUP, LTD.

A handwritten signature in black ink, appearing to be 'Yiu Ming Yiu', written in a cursive style.

Director Name: YIU MING YIU  
No. of Shares: 71,460,300

A handwritten number '204318' in black ink, written in a cursive style.